Fluorine News and Research

RSS

Groundbreaking molecular imaging agent developed to trace advanced prostate cancer

Anti-androgen hormonal therapy, also called chemical castration, can be an important defense against further disease progression for patients with prostate cancer that has traveled and grown in other areas, or metastasized-but some cases simply do not respond to this treatment.

10 Jun 2014

New "18F radiotracers" to detect and track certain diseases in patients

Radioactivity is usually associated with nuclear fallout or comic-book spider bites, but in very small amounts it can be a useful tool for diagnosing diseases.

22 May 2014

AAA gets orphan drug designation status for radiopharmaceutical, Gallium-68 DOTATATE

Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM), announced today that they have received orphan drug designation status for their radiopharmaceutical, Gallium-68 DOTATATE.

4 Mar 2014

New Dartmouth study finds many people unnecessarily fear low amounts of chemicals in their food

When it comes to what's for dinner - or breakfast and lunch for that matter-- many people suffer from chemophobia, an irrational fear of natural and synthetic chemicals that pose no risk to our health, a Dartmouth study finds.

16 Aug 2013

Perfluoroalkyl substances are crossing blood brain barrier of polar bears

PerFluoroAlkyl Substances (PFASs) and precursor compounds have been used in a wide variety of commercial and industrial products over the past six decades. Applications include water and oil repellent coatings, e.g. for textiles, paper products, carpets and food packaging, pharmaceuticals and surfactants in cleaning products and fire-fighting foams.

25 Jul 2013

Results of post-mortem brain tissue study using Navidea's NAV4694 imaging agent presented at AAIC 2013

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that researchers at McGill Center for Studies in Aging, Douglas Research Institute and Montreal Neurological Institute presented results of a post-mortem brain tissue study using Navidea's investigational Fluorine-18 labeled β-amyloid imaging agent, NAV4694, during the Alzheimer's Association International Conference in Boston, MA.

23 Jul 2013

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

Imaging techniques in cancer medicine provide far more than merely information on the scale and location of cancerous ulcers. There are modern methods that additionally characterise the tumour cells precisely, for instance by specific molecules they carry on their surface. Such additional information gives doctors key clues as to the precise cancer type and enables them to predict the probability that a patient will respond to a particular form of therapy.

6 Jul 2013

El Lilly calls for Medicare coverage of beta-amyloid imaging agents for Alzheimer's disease

Eli Lilly and Company today announced that the Centers for Medicare & Medicaid Services (CMS) has issued a draft decision proposing Coverage with Evidence Development for the use of beta-amyloid positron emission tomography (PET) imaging agents. Beta-amyloid imaging agents are used to evaluate patients with cognitive impairment for Alzheimer's Disease and other causes of cognitive decline.

5 Jul 2013

Pelchem and Linde team up to advance MEMS systems

Linde Electronics, the global electronics business of The Linde Group, has strengthened its material support for electronics manufacturing by announcing a strategic partnership with Pelchem, the global fluorochemicals specialist, to accelerate the development of Micro-Electro-Mechanical Systems (MEMS).

22 Apr 2013

Navidea commences enrollment in NAV4694 Phase 2b study to detect erebral β-amyloid plaque

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced in its Phase 2b, open-label, safety and efficacy positron emission tomography imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment.

28 Mar 2013

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

Influenza or flu for short is caused by a family of viruses, which can be called influenza A or influenza B. Influenza A viruses are found in humans, animals – like swine and horses- and mostly aquatic birds. Influenza B is only found in humans.

11 Mar 2013

Study shows how nanoparticles can be formed to efficiently carry cancer drugs to tumor cells

Small particles loaded with medicine could be a future weapon for cancer treatment. A recently-published study shows how nanoparticles can be formed to efficiently carry cancer drugs to tumor cells. And because the particles can be seen in MRI images, they are traceable.

7 Mar 2013

Study shows how theranostic nanoparticles can effectively deliver cancer drugs to tumour cells

Tiny particles filled with a drug could be a new tool for treating cancer in the future. A new study published by Swedish scientists in Particle & Particle Systems Characterization shows how such nanoparticles can be combined to secure the effective delivery of cancer drugs to tumour cells - and how they can be given properties to make them visible in MR scanners and thus rendered trackable.

1 Mar 2013

Combination of imaging and biomarker tests helps predict Alzheimer's in patients with MCI

Employing a combination of imaging and biomarker tests improves the ability of doctors to predict Alzheimer's in patients with mild cognitive impairment, according to researchers at Duke Medicine.

11 Dec 2012

Navidea commences enrollment in [18F]NAV4694 Phase 2 study for Alzheimer's

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced at two sites participating in its Phase 2, open-label, safety and efficacy PET imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with probable Alzheimer's disease (AD).

19 Sep 2012

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

8 Jun 2012

Cardinal Health to produce new AD diagnostic imaging agent, Amyvid

Cardinal Health today announced that it will manufacture and distribute Amyvid, Eli Lilly and Company's new diagnostic imaging agent that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. The commercial launch of Amyvid is scheduled for June 1, 2012.

2 Jun 2012

Lilly, Avid receive FDA approval for Amyvid to treat Alzheimer's

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.

7 Apr 2012

International Isotopes 2011 revenue increases 55% to $9,462,012

International Isotopes Inc. announces the financial results for fiscal year ended December 31, 2011, and plans for a shareholder conference call to review these results and provide a general update on the business performance and plans of the Company in 2012.

29 Mar 2012

Banner Alzheimer's Institute presents results from Navidea AZD4694 study at 6th Annual HAI

Navidea Biopharmaceuticals, Inc. today announced that the Banner Alzheimer's Institute, Phoenix, AZ, made two presentations of results from an AstraZeneca-sponsored study on the assessment of Navidea's late-stage radiopharmaceutical imaging candidate, AZD4694, at the 6th Annual Human Amyloid Imaging Meeting (HAI), in Miami, FL.

20 Jan 2012